Hormonal
Expanded access to GLP-1 and GIP/GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for eligible populations could avert approximately 42,000 deaths annually in the US by reducing obesity-related mortality.
If you are eligible for GLP-1/GIP agonists based on BMI and comorbidities, expanding insurance coverage and manufacturing capacity could save tens of thousands of lives annually by reducing obesity-related mortality. Current barriers like cost and supply shortages prevent many from accessing these life-saving treatments.
Specifically, we project that with expanded access, over 42,000 deaths could be averted annually, including more than 11,000 deaths among people with type 2 diabetes.
Why this rating
The study is a modeling projection based on established hazard ratios and prevalence data, not a randomized controlled trial of the intervention itself, but uses robust epidemiological inputs.
Source
Estimating the lives that could be saved by expanded access to weight-loss drugs
Abhishek Pandey et al. · Proceedings of the National Academy of Sciences · 2024
DOI 10.1073/pnas.2412872121
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →